Drugs / AlloEx exosomes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07226726 | Jan 2025 → Dec 2028 expected | congenital myasthenic syndrome | The Foundation for Orthopaedics and Regenerative Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT07105371 | Jul 2024 → Mar 2025 | movement disorder | The Foundation for Orthopaedics and Regenerative Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloEx exosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226726 ↗ |
| Known as | AlloEx Exosome | “18 patients with ALS, Kennedy Disease, Congenital Myasthenic Syndrome, or Lewy Body Dementia had 32 AlloEx Exosome® treatments to assess safety, attenuation of disease, and...” PMID 41278139 ↗ Oct 2025 |
| Modality | Other / unclassified | “exosomes derived from mesenchymal stem cells” NCT07105371 ↗ |
| Route | Intranasal | “This is an intranasal treatment of exosomes derived from mesenchymal stem cells.” NCT07105371 ↗ |